Send us Fan Mail

Thankfully for patients, treatments for amyloidosis continue to advance. One of the newest is CAR-T cell therapy for AL Light Chain amyloidosis. According to the Cleveland Clinic, this therapy targets the B-cell maturation antigen (BCMA) on the surface of the plasma cells that cause the disease. Early results are highly promising and may provide quick reduction in light chains. In this episode Mackenzie chats with Rhonda about her experience preparing for, and going through, CAR-T cell therapy. If you want to hear from a patient about a new and exciting treatment – have a listen. For an overview of amyloidosis, please see episode 2 (for clinicians) or episode 3 (for patients).